<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oxid Med Cell Longev</journal-id><journal-id journal-id-type="iso-abbrev">Oxid Med Cell Longev</journal-id><journal-id journal-id-type="publisher-id">OMCL</journal-id><journal-title-group><journal-title>Oxidative Medicine and Cellular Longevity</journal-title></journal-title-group><issn pub-type="ppub">1942-0900</issn><issn pub-type="epub">1942-0994</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29743980</article-id><article-id pub-id-type="pmc">5878880</article-id><article-id pub-id-type="doi">10.1155/2018/4147320</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Long-Term Resveratrol Supplementation as a Secondary Prophylaxis for Stroke</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fodor</surname><given-names>Katalin</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0296-6592</contrib-id><name><surname>Tit</surname><given-names>Delia Mirela</given-names></name><email>mirela_tit@yahoo.com</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1788-6042</contrib-id><name><surname>Pasca</surname><given-names>Bianca</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1252-0057</contrib-id><name><surname>Bustea</surname><given-names>Cristiana</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7568-5222</contrib-id><name><surname>Uivarosan</surname><given-names>Diana</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3315-2364</contrib-id><name><surname>Endres</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Iovan</surname><given-names>Ciprian</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4341-2713</contrib-id><name><surname>Abdel-Daim</surname><given-names>Mohamed M.</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3236-1292</contrib-id><name><surname>Bungau</surname><given-names>Simona</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Pharmacy Department, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania</aff><aff id="I2">
<sup>2</sup>Preclinical Disciplines Department, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania</aff><aff id="I3">
<sup>3</sup>Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt</aff><aff id="I4">
<sup>4</sup>Department of Ophthalmology and Micro-technology, Yokohama City University, Yokohama, Japan</aff><author-notes><fn fn-type="other"><p>Academic Editor: Mohammad A. Kamal</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>18</day><month>3</month><year>2018</year></pub-date><volume>2018</volume><elocation-id>4147320</elocation-id><history><date date-type="received"><day>18</day><month>12</month><year>2017</year></date><date date-type="rev-recd"><day>28</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>5</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Katalin Fodor et al.</copyright-statement><copyright-year>2018</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Stroke is a leading cause of mortality worldwide, as well as a source of long-term disabilities and huge socioeconomic costs. This study investigates the effects of resveratrol, an antioxidant supplement, on blood pressure, weight status, glucose, and lipid profile in patients who had a stroke in the last 12 months. Two hundred and twenty-eight patients were divided into three groups: group I received only allopathic treatment (control group), while groups II and III received allopathic treatment with a daily supplementation of oral resveratrol (100 and 200&#x02009;mg, resp.) for 12 months. In all groups, the changes of the studied parameters were monitored at 6 and 12 months from the initial evaluation. In groups II and III, resveratrol induced significant changes (<italic>p</italic> &#x0003c; 0.05) in the blood pressure, body mass index, as well as all parameters of the lipid profile, and glucose (in nondiabetic patients), compared to the control group. The supplementation of the allopathic treatment with resveratrol had a beneficial effect on all monitored parameters, which serve as major risk factors for stroke.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Neurodegenerative, circulatory, and cardiovascular diseases and cancers are considered as direct consequence of the complex of phenomena, named &#x0201c;oxidative stress&#x0201d; [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>]. Among these, stroke represents a leading cause of mortality worldwide and a major source of long-term disabilities and huge socioeconomic costs [<xref rid="B4" ref-type="bibr">4</xref>]. A recent study has revealed that about 90% of strokes can be attributed to the presence of 10 risk factors, including high blood pressure (BP), dyslipidemias, consumption of toxic substances (alcohol and tobacco), obesity, daily stress, sedentariness, and diabetes mellitus [<xref rid="B5" ref-type="bibr">5</xref>].</p><p>During the pathophysiology of stroke, reactive oxygen species (ROS) are generated, which can trigger chain reactions that destroy the neuronal membranes [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. There are cumulative evidences suggesting that ROS can damage the cellular components [<xref rid="B8" ref-type="bibr">8</xref>], enhance the production of inflammatory mediators which in turn can lead to additional oxidative stress [<xref rid="B9" ref-type="bibr">9</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>], and are involved in all the pathophysiological stages of neuronal death [<xref rid="B13" ref-type="bibr">13</xref>]. During ischemia, mitochondria (the main ROS-generating cellular components) suffer dysfunction, which causes an increase in oxidative stress. Increased production of ROS through mitochondria plays a role in the pathogenesis of stroke through direct damage to biomolecules resulting in necrosis, necroptosis and apoptosis, damaged endothelium-dependent vasodilator mechanisms, induction of mitochondrial permeability of transition, and interrupted excitation-contraction coupling [<xref rid="B14" ref-type="bibr">14</xref>].</p><p>Reactive oxygen species have an important role in normal physiological processes, being also implicated in a lot of disease processes, where they mediate damage to cell structures, including membranes, lipids, deoxyribonucleic acid (DNA), and proteins. Oxidative stress has an important role in the pathogenesis of ischemic brain injury that follows a cerebrovascular attack, having as goal the cerebral vasculature. The primary reactive oxygen species (like superoxide) and its derivatives, in animal models with ischemic stroke, cause vasodilatation by opening the potassium channels, altering the vascular reactivity, and breaking down the blood-brain barrier [<xref rid="B15" ref-type="bibr">15</xref>].</p><p>Diabetes mellitus and atherosclerosis are diseases that are associated with chronic inflammation produced by ROS [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B16" ref-type="bibr">16</xref>]. Consequently, stroke therapies should also consider secondary prophylaxis by addressing ROS on the medium and long term.</p><p>To neutralize these free radicals, the presence of potentially neutralizing agents (antioxidants) in the body is needed [<xref rid="B17" ref-type="bibr">17</xref>]. Particular attention is paid to the use of natural antioxidant agents that can be administered safely in humans in determined, verified, and standardized doses [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>]. Resveratrol (3,5,4&#x02032;-trihydroxy-trans-diphenyl-ethylene) is well-known as a natural antioxidant, effective in combating oxidative stress and related inflammation [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. Due to its antioxidant effect, this substance can neutralize free radicals in the human body, thus reducing the resultant cellular aging process [<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B24" ref-type="bibr">24</xref>]. Resveratrol possesses phenolic functions (Ar-OH) susceptible to block-connect hydroperoxide radicals resulting from lipid peroxidation [<xref rid="B25" ref-type="bibr">25</xref>].</p><p>Numerous studies have shown the effectiveness of resveratrol in improving health and preventing chronic diseases. However, it is unclear whether these effects persist with prolonged administration of resveratrol [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B26" ref-type="bibr">26</xref>]. This study investigates the effects of long-term resveratrol supplementation on BP, weight status, glucose, and lipid profile in patients who had a stroke in the last 12 months.</p></sec><sec id="sec2"><title>2. Methods</title><sec id="sec2.1"><title>2.1. Study Design</title><p>This study included patients who had first stroke in the last 12 months, hospitalized for recovery treatment during 2011&#x02013;2015 (patients were recruited each year during 5 years, each patient being under observation for a year). All patients were clinically stabilized after stroke. When they were included in this study, the patients were hospitalized in the <italic>Baile Felix Clinical Rehabilitation Hospital</italic> where they followed a complex medical physical rehabilitation program that imposed restrictions for BP values.</p><p>The research was conducted in accordance with the WMA Ethical Declaration of Helsinki and was approved by the Ethics Commission of the Council of Medicine and Pharmacy Faculty, University of Oradea, Romania. Each patient included in this study signed an informed consent form, before the inclusion.</p><p>Two hundred and twenty-eight patients were divided into three groups: <italic>group I</italic> (control), (<italic>n</italic> = 92 patients) who underwent allopathic (medical) treatment combined with medical physical rehabilitation, while <italic>groups II</italic> (<italic>n</italic> = 81 patients) and <italic>III</italic> (<italic>n</italic> = 55 patients) received allopathic treatment and medical physical rehabilitation, combined with a 12-month supplementation with an oral daily dose of resveratrol (100 and 200&#x02009;mg/patient, resp.). The patients were distributed into groups using the method of selection for each group, depending on the patient's willingness of taking 100 or 200&#x02009;mg resveratrol, according to every patient's history and clinical characteristics, so that there were no significant differences between groups. Allopathic treatment was individualized for each patient, depending on the clinical characteristics and associated pathology. All patients were evaluated initially, at 6 months and at 12 months from the beginning of the treatment. The following parameters were monitored: BP, weight status, lipid profile (total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides), and glucose profile.</p></sec><sec id="sec2.2"><title>2.2. Clinical Investigations</title><sec id="sec2.2.1"><title>2.2.1. Blood Pressure Measurement</title><p>Blood pressure measurement was performed following the 2007 Guidelines for the Management of Arterial Hypertension [<xref rid="B27" ref-type="bibr">27</xref>].</p></sec><sec id="sec2.2.2"><title>2.2.2. Body Mass Index (BMI) Determination</title><p>To determine the patients' weight status, the BMI was calculated using the following equation (BMI&#x02009;=&#x02009;weight in kilograms divided by the square of height in meters, expressed in kg/m<sup>2</sup>) [<xref rid="B28" ref-type="bibr">28</xref>].</p></sec></sec><sec id="sec2.3"><title>2.3. Biochemical Analysis</title><p>Blood samples were obtained in the morning after a 12&#x02013;14-hour meal break and were used to evaluate the levels of total cholesterol, triglycerides, HDL and LDL cholesterol, basal glucose, and glycosylated hemoglobin (HbA1c).</p><sec id="sec2.3.1"><title>2.3.1. Lipid Profile</title><p>The cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol assays were performed on the Beckman Coulter AU680 analyser using Beckman Coulter reagents, produced by Beckman Coulter Inc., Ireland. The methods of determination included the oxidase-peroxidase method for cholesterol, enzymatic glycerol-3-phosphate oxidase method for triglycerides, and colorimetric direct method for HDL and LDL cholesterol.</p></sec><sec id="sec2.3.2"><title>2.3.2. Fasting Blood Glucose</title><p>Basal glucose was determined by the hexokinase method, the values on an empty stomach being used for the selection of all subjects. A normal level of basal blood glucose was considered a plasmatic concentration of &#x0003c;100&#x02009;mg/dL [<xref rid="B29" ref-type="bibr">29</xref>].</p></sec><sec id="sec2.3.3"><title>2.3.3. Glycosylated Hemoglobin</title><p>Glycosylated hemoglobin was determined only for diabetic patients. It is a real image of glucose control over a period of 90&#x02013;120 days retrospectively [<xref rid="B26" ref-type="bibr">26</xref>]. Determination was performed from venous blood collected on EDTA anticoagulant by HPLC (Gold Standard) using BioRad D-10 equipment and reagents.</p></sec><sec id="sec2.3.4"><title>2.3.4. Quality Control</title><p>The internal quality control was performed according to ISO 15189: 2013 standard. Variation coefficients were as follows: cholesterol CV%&#x02009;=&#x02009;2.05, triglyceride CV%&#x02009;=&#x02009;1.95, HDL cholesterol CV%&#x02009;=&#x02009;2.29, LDL cholesterol CV%&#x02009;=&#x02009;1.74, glucose CV%&#x02009;=&#x02009;2.05, and HbA1c CV%&#x02009;=&#x02009;0.82.</p></sec></sec><sec id="sec2.4"><title>2.4. Statistical Analysis</title><p>Statistical analysis was done using EPIINFO, version 6.0, a program of the Center for Disease Control and Prevention from Atlanta, adapted to the medical statistics processing. Average parameter values, frequency ranges, standard deviations, and statistical significance tests by the Student method (<italic>t</italic> test) and &#x003c7;<sup>2</sup> were calculated.</p><p>The distribution of the tests is similar to normal, being used by assumptions involving numerical data. The <italic>t</italic> test used was paired <italic>t</italic> test. In order to obtain an indicator independent of the measurement units of the two variables, the Bravais-Pearson correlation coefficient was used. Statistical significance was assigned at a <italic>p</italic> value of &#x0003c;0.05.</p><p>In order to interpret the magnitude of change in parameters at different time points, the &#x0201c;effect size&#x0201d; (ES) was measured. Based on statistical literature, the interpretation of this index was compiled, namely, small ES&#x02009;=&#x02009;0.20, medium ES&#x02009;=&#x02009;0.50, and large ES&#x02009;=&#x02009;0.80. When expressing the findings of a quantitative study, ES is important because a <italic>p</italic> value can identify if there is an effect but cannot reveal its magnitude [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>].</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Patients' Characteristics</title><p>In terms of demographic and clinical characteristics, there were no significant differences (<italic>p</italic> &#x0003e; 0.05) between the three groups (<xref ref-type="table" rid="tab1">Table 1</xref><bold>)</bold>.</p></sec><sec id="sec3.2"><title>3.2. Clinical Evaluations</title><sec id="sec3.2.1"><title>3.2.1. The Effect of Resveratrol on BP</title><p>Initially, there were no significant differences (<italic>p</italic> &#x0003e; 0.05) in the mean BP values between the three experimental groups (<xref ref-type="table" rid="tab2">Table 2</xref>).</p><p>
<italic>(1) Systolic BP</italic>. In the group receiving 100&#x02009;mg resveratrol, the systolic BP value decreased from 148.02&#x02009;mmHg to 143.12&#x02009;mmHg at 6 months (<italic>p</italic> &#x0003c; 0.05) and to 139.85&#x02009;mmHg in the next 6 months (<italic>p</italic> &#x0003c; 0.05). In the group receiving 200&#x02009;mg resveratrol, the systolic BP value decreased from 149.21&#x02009;mmHg to 142.02&#x02009;mmHg at 6 months (<italic>p</italic> &#x0003c; 0.05) and to 139.35&#x02009;mmHg in the next 6 months (<italic>p</italic> &#x0003c; 0.05). In the control group, systolic BP values decreased from 148.42&#x02009;mmHg to 146.10&#x02009;mmHg at 6 months (<italic>p</italic> &#x0003e; 0.05) and to 145.32&#x02009;mmHg in the next 6 months (<italic>p</italic> &#x0003e; 0.05).</p><p>Comparing data (<xref ref-type="table" rid="tab2">Table 2</xref>) at the initial evaluation and at 12 months of treatment, the ES was 0.53 in the group receiving 100&#x02009;mg resveratrol, ES&#x02009;=&#x02009;0.53 (<italic>p</italic> &#x0003c; 0.05) and 0.65 in the group receiving 200&#x02009;mg resveratrol (<italic>p</italic> &#x0003c; 0.05), while in the control group, ES was 0.20 (<italic>p</italic> &#x0003e; 0.05).</p><p>
<italic>(2) Diastolic BP</italic>. In the group receiving 100&#x02009;mg resveratrol, the diastolic BP value decreased from 88.29&#x02009;mmHg to 85.89&#x02009;mmHg at 6 months (<italic>p</italic> &#x0003e; 0.05) and to 84.27&#x02009;mmHg in the next 6 months (<italic>p</italic> &#x0003e; 0.05). In the group receiving 200&#x02009;mg resveratrol, the diastolic BP value decreased from 88.47&#x02009;mmHg to 85.91&#x02009;mmHg at 6 months (<italic>p</italic> &#x0003e; 0.05) and 84.10&#x02009;mmHg in the next 6 months (<italic>p</italic> &#x0003e; 0.05). In the control group, the diastolic BP value decreased from 87.61&#x02009;mmHg to 86.39&#x02009;mmHg at 6 months (<italic>p</italic> &#x0003e; 0.05) and 85.67&#x02009;mmHg in the next 6 months (<italic>p</italic> &#x0003e; 0.05), respectively (<xref ref-type="table" rid="tab2">Table 2</xref>).</p><p>Comparing data at the initial evaluation and at 12 months of treatment, ES was 0.37 in the group with 100&#x02009;mg resveratrol (<italic>p</italic> &#x0003c; 0.05), 0.39 in the group receiving 200&#x02009;mg resveratrol (<italic>p</italic> &#x0003c; 0.05), and 0.17 for the control group without resveratrol supplementation (<italic>p</italic> &#x0003e; 0.05).</p></sec><sec id="sec3.2.2"><title>3.2.2. The Effect of Resveratrol on the Weight Status and BMI</title><p>Initially, there were no significant differences (<italic>p</italic> &#x0003e; 0.05) in BMI values between the two experimental groups. After a 12-month administration of resveratrol at 100 and 200&#x02009;mg, we recorded a significant decrease (<italic>p</italic> &#x0003c; 0.05) in the mean BMI values, compared to the control group (<xref ref-type="table" rid="tab3">Table 3</xref>).</p><p>The mean BMI values decreased after 6 months in the group receiving 100&#x02009;mg resveratrol from 29.47&#x02009;kg/m<sup>2</sup> to 27.97&#x02009;kg/m<sup>2</sup> (<italic>p</italic> &#x0003e; 0.05), resulting in an ES&#x02009;=&#x02009;0.35; in the group receiving 200&#x02009;mg resveratrol, from 29.50&#x02009;kg/m<sup>2</sup> to 27.56&#x02009;kg/m<sup>2</sup> (<italic>p</italic> &#x0003e; 0.05), resulting in an ES&#x02009;=&#x02009;0.45; in the nonresveratrol group, the BMI had a minimal decrease from 29.95&#x02009;kg/m<sup>2</sup> to 29.42&#x02009;kg/m<sup>2</sup> (<italic>p</italic> &#x0003e; 0.05), resulting in an ES&#x02009;=&#x02009;0.12.</p><p>In the next 6 months, in the group receiving 100&#x02009;mg resveratrol, a decrease in BMI was noticed from 27.97&#x02009;kg/m<sup>2</sup> to 26.75&#x02009;kg/m<sup>2</sup> (<italic>p</italic> &#x0003e; 0.05), resulting in an ES&#x02009;=&#x02009;0.27; in the group receiving 200&#x02009;mg resveratrol, a decrease in BMI was noticed from 27.56&#x02009;kg/m<sup>2</sup> to 25.77&#x02009;kg/m<sup>2</sup> (<italic>p</italic> &#x0003c; 0.05), resulting in an ES&#x02009;=&#x02009;0.42; in the group without resveratrol, a decrease in BMI was noticed from 29.42&#x02009;kg/m<sup>2</sup> to 29.31&#x02009;kg/m<sup>2</sup> (<italic>p</italic> &#x0003e; 0.05), resulting in an ES&#x02009;=&#x02009;0.02.</p><p>Comparing data at the initial evaluation and at 12 months of treatment, ES was 0.64 (from 29.47&#x02009;kg/m<sup>2</sup> to 26.75&#x02009;kg/m<sup>2</sup>, <italic>p</italic> &#x0003c; 0.05) in the group receiving 100&#x02009;mg resveratrol, 0.87 (from 29.50&#x02009;kg/m<sup>2</sup> to 25.77&#x02009;kg/m<sup>2</sup>, <italic>p</italic> &#x0003c; 0.05) in the group receiving 200&#x02009;mg resveratrol, and 0.14 (from 29.95&#x02009;kg/m<sup>2</sup> to 29.31&#x02009;kg/m<sup>2</sup>, <italic>p</italic> &#x0003e; 0.05) in the group without resveratrol supplementation (<xref ref-type="table" rid="tab3">Table 3</xref>).</p></sec></sec><sec id="sec3.3"><title>3.3. Biochemical Analysis</title><sec id="sec3.3.1"><title>3.3.1. The Effect of Resveratrol on the Lipid Profile</title><p>In all groups, the lipid profile improved significantly both at 6 months and at 12 months (<italic>p</italic> &#x0003c; 0.05). In the resveratrol groups, the lipid profile improved significantly over the 12 months (<italic>p</italic> &#x0003c; 0.05), compared with the control group (<xref ref-type="table" rid="tab4">Table 4</xref>). After 12 months, resveratrol administration irrespective of the dose had a substantial effect on all lipid profile parameters, especially on triglycerides (ES&#x02009;=&#x02009;1.81 at 100&#x02009;mg and ES&#x02009;=&#x02009;1.95 at 200&#x02009;mg) and serum cholesterol (ES&#x02009;=&#x02009;1.51 at 100&#x02009;mg and ES&#x02009;=&#x02009;1.63 at 200&#x02009;mg). For the control group, the ES was greater than 1 as well, in the case of triglycerides and serum cholesterol (ES&#x02009;=&#x02009;1.39 and ES&#x02009;=&#x02009;1.07, resp.). Compared to the control group, the effect of resveratrol 100&#x02009;mg was 2.02 times greater for HDL cholesterol (ES&#x02009;=&#x02009;1.25 versus ES&#x02009;=&#x02009;0.62) and of 2.34 for LDL cholesterol (ES&#x02009;=&#x02009;1.24 versus ES&#x02009;=&#x02009;0.53). Also, compared to the control group, the effect of resveratrol 200&#x02009;mg was 2.11 times greater for HDL-cholesterol (ES&#x02009;=&#x02009;1.31 versus ES&#x02009;=&#x02009;0.62) and of 2.42 times for LDL-cholesterol (ES&#x02009;=&#x02009;1.28 versus ES&#x02009;=&#x02009;0.53).</p></sec><sec id="sec3.3.2"><title>3.3.2. The Effect of Resveratrol on the Glycemic Profile</title><p>
<italic>(1) Basal Glycemia</italic>. In diabetic patients, blood glucose levels decreased insignificantly (<italic>p</italic> &#x0003e; 0.05) after 6 months, in the group receiving 100&#x02009;mg resveratrol (from 142.18&#x02009;mg/dL to 136.29&#x02009;mg/dL, ES&#x02009;=&#x02009;0.39) and in the group receiving 200&#x02009;mg (from 142.46&#x02009;mg/dL to 136.21&#x02009;mg/dL, ES&#x02009;=&#x02009;0.41). The decrease was significant compared to the control group where the blood glucose values had a minimal decrease (from 142.47&#x02009;mg/dL to 141.81&#x02009;mg/dL, ES&#x02009;=&#x02009;0.04).</p><p>In the following 6 months, blood glucose decreased in the group receiving 100&#x02009;mg resveratrol from 136.29 to 134.24&#x02009;mg/dL, ES&#x02009;=&#x02009;0.17, and in the group receiving 200&#x02009;mg from 136.21 to 133.89&#x02009;mg/dL, ES&#x02009;=&#x02009;0.16. In the group without resveratrol, the effect was ES&#x02009;=&#x02009;0.08 (from 141.81 to 140.58&#x02009;mg/dL).</p><p>Comparing the results of the initial evaluation and 12 months of assessment in diabetic patients, ES was 0.52 (from 142.18&#x02009;mg/dL to 134.24&#x02009;mg/dL, <italic>p</italic> &#x0003e; 0.05) in the group receiving 100&#x02009;mg resveratrol, 0.56 in the group receiving 200&#x02009;mg resveratrol (from 142.46&#x02009;mg/dL to 133.89&#x02009;mg/dL, <italic>p</italic> &#x0003e; 0.05) and 0.12 (from 142.47&#x02009;mg/dL to 140.58&#x02009;mg/dL, <italic>p</italic> &#x0003e; 0.05) in the group without resveratrol supplementation.</p><p>In nondiabetic patients, blood glucose levels decreased significantly (<italic>p</italic> &#x0003c; 0.05) after 6 months in the group receiving 100&#x02009;mg of resveratrol (from 96.67&#x02009;mg/dL to 91.23&#x02009;mg/dL, ES&#x02009;=&#x02009;0.48) and in the group receiving 200&#x02009;mg (from 96.98&#x02009;mg/dL to 91.21&#x02009;mg/dL, ES&#x02009;=&#x02009;0.51). The decrease was significant from the baseline and from the control group where the blood glucose values had a minimal decrease (from 95.71&#x02009;mg/dL to 94.55&#x02009;mg/dL, ES&#x02009;=&#x02009;0.1).</p><p>In the following 6 months, blood glucose decreased in the group receiving 100&#x02009;mg resveratrol from 91.23 to 87.12&#x02009;mg/dL, ES&#x02009;=&#x02009;0.38, in the group receiving 200&#x02009;mg from 91.21 to 86.11&#x02009;mg/dL, ES&#x02009;=&#x02009;0.48, and in the group without resveratrol, ES&#x02009;=&#x02009;0.11 (from 94.55 to 93.33&#x02009;mg/dL). In both groups with resveratrol, the decrease was significant compared to the value at six months and compared to the control group (<xref ref-type="table" rid="tab5">Table 5</xref>).</p><p>Comparing the results of the initial evaluation and 12 months of assessment in nondiabetic patients, ES was 0.85 (from 96.67&#x02009;mg/dL to 87.12&#x02009;mg/dL, <italic>p</italic> &#x0003c; 0.05) in the group receiving 100&#x02009;mg resveratrol, 0.97 (from 96.98&#x02009;mg/dL to 86.11&#x02009;mg/dL, <italic>p</italic> &#x0003c; 0.05) in the group receiving 200&#x02009;mg resveratrol, and 0.20 (from 95.71&#x02009;mg/dL to 93.33&#x02009;mg/dL, <italic>p</italic> &#x0003e; 0.05) in the group without resveratrol supplementation.</p><p>
<italic>(2) Glycosylated Hemoglobin</italic>. Glycated hemoglobin values decreased after 6 months as follows: in the group receiving 100&#x02009;mg resveratrol from 7.13% to 6.72% (<italic>p</italic> &#x0003e; 0.05, ES&#x02009;=&#x02009;0.27); in the group receiving 200&#x02009;mg resveratrol from 7.15% to 6.66% (<italic>p</italic> &#x0003e; 0.05, ES&#x02009;=&#x02009;0.33); and in the group without resveratrol supplementation, there was a minimal decrease in HbA1c values (from 7.10% to 7.09%, <italic>p</italic> &#x0003e; 0.05, ES&#x02009;=&#x02009;0.01).</p><p>In the next 6 months, a decrease in HbA1c mean values was noticed from 6.72% to 6.61% (<italic>p</italic> &#x0003e; 0.05, ES&#x02009;=&#x02009;0.08) and from 6.66% to 6.55% (<italic>p</italic> &#x0003e; 0.05, ES&#x02009;=&#x02009;0.08) in the group receiving 200&#x02009;mg resveratrol. In the group without resveratrol supplementation, ES was 0.03 (from 7.09% to 7.05%, <italic>p</italic> &#x0003e; 0.05) (<xref ref-type="table" rid="tab6">Table 6</xref>).</p><p>Comparing data at the initial evaluation and at 12 months of treatment, ES was 0.34 (from 7.13% to 6.61%, <italic>p</italic> &#x0003e; 0.05) in the group receiving 100&#x02009;mg resveratrol, 0.40 (from 7.15% to 6.55%, <italic>p</italic> &#x0003e; 0.05) in the group receiving 200&#x02009;mg resveratrol, and 0.03 (from 7.10% to 7.05%, <italic>p</italic> &#x0003e; 0.05) in the group without resveratrol supplementation.</p></sec></sec></sec><sec id="sec4"><title>4. Discussion</title><p>One of the most prevalent cardiovascular illness is stroke. This is a main problem not only in matter of health, both in terms of sequelae and the destructive impact on the quality of life of the patient, implicitly on his or her relatives, but also in the point of view of increasing mortality.</p><p>Comprehensive research over the last few decades has discovered multiple mechanisms by which resveratrol changes cardiovascular risk factors [<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>]. Diabetes, hypercholesterolemia, and hypertension, by decreasing bioactive nitric oxide, lead to high production of reactive oxygen species in vessel walls. Endothelial dysfunction is a significant mechanism of cerebrovascular injury, deriving in part from the excessive generation of reactive oxygen species [<xref rid="B32" ref-type="bibr">32</xref>].</p><p>Here, we show that long-term resveratrol supplementation in patients poststroke had a beneficial effect on these parameters that serve as major risk factors for stroke.</p><p>To evaluate the long-term dose-dependent resveratrol potential in the secondary prevention of stroke, in this study, we compared the effects of two different doses of resveratrol in terms of effectiveness on BP, weight status, lipid profile, and glucose profile, in patients who have suffered a stroke in the past 12 months.</p><p>We chose doses of 100&#x02009;mg and 200&#x02009;mg resveratrol/day, respectively, due to the fact that it has been shown that doses of resveratrol lower than 0.5&#x02009;g per person may be sufficient to decrease blood glucose levels, improve insulin action, and generate cardioprotective effect and other favorable effects [<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>]. Moreover, some studies imply that in certain cases, resveratrol can be more efficient in lower doses compared to the effect produced by this compound in higher doses [<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>]. Nevertheless, studies upon the toxicity of resveratrol in humans reveal that doses up to 0.5&#x02009;g per day for long periods may determine only reversible and moderate side effects, being well tolerated [<xref rid="B38" ref-type="bibr">38</xref>].</p><p>We recorded significant decreases in BP, BMI, lipid profile parameters, and glucose in patients, treated with a daily oral dose of 100 or 200&#x02009;mg resveratrol for a year, as compared to the control group. The effect of resveratrol in 200&#x02009;mg dose was significantly better than in 100&#x02009;mg dose, on triglyceride values alone. Patients were monitored for a period of 12 months, during which no new vascular attack occurred in any group; however, in the resveratrol groups, the monitored parameters were significantly improved. Previous studies have revealed that stroke risk factor identification and treatment can considerably prevent long-term morbidity and mortality and can diminish ischemic stroke after a first stroke [<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>].</p><p>Besides age, the most significant cardiovascular risk factor for developing both hemorrhagic and ischemic stroke is hypertension. In addition, hypertension predisposes to risk of cardiac diseases and atherosclerosis, thereby determining cerebral embolism. The inflammatory mechanisms hold an important role in the progression and pathogenesis of atherosclerosis, thrombosis, plaque rupture, and stroke [<xref rid="B40" ref-type="bibr">40</xref>]. As we have previously mentioned, endothelial dysfunction is regarded as an important mechanism for cerebrovascular damages [<xref rid="B32" ref-type="bibr">32</xref>].</p><p>Several studies have reported an increased level of lipid peroxidation and oxidative stress biomarkers in patients with essential or secondary hypertension [<xref rid="B41" ref-type="bibr">41</xref>&#x02013;<xref rid="B44" ref-type="bibr">44</xref>]. Other studies showed that the production of H<sub>2</sub>O<sub>2</sub> and 13-hydroxyoctadecadienoic acid, a ROS production marker, is significantly higher in these patients than in subjects with normal BP [<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>]. Therefore, due to its antioxidant activity, resveratrol may have beneficial effects in reducing high BP. In a study performed on 97 patients, Theodotou et al. concluded that adding resveratrol to the standard antihypertensive treatment effectively reduces BP [<xref rid="B47" ref-type="bibr">47</xref>]. This may occur through increasing the production of nitric oxide in blood vessels, where it activates the guanylate cyclase enzyme, which facilitates vasodilatation [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B48" ref-type="bibr">48</xref>].</p><p>Our study demonstrated that the association of resveratrol to allopathic treatment for 12 months resulted in a significant decrease in BP (<italic>p</italic> &#x0003c; 0.05) in poststroke patients.</p><p>The evaluations at 6 months and 12 months did not indicate significant differences between the two batches with different doses of resveratrol on the effect on BP.</p><p>Multiple studies have demonstrated that resveratrol is able to determine cell cycle arrest and counteracts adipogenesis, in the same time having a proapoptotic effect in adipocytes of mice and humans [<xref rid="B49" ref-type="bibr">49</xref>].</p><p>Resveratrol is a substance with multiple desirable antiobesity effects on adipocytes in body storage tissues. It also diminishes adipogenesis and viability in preadipocyte maturation, which is mediated by the regulation of specific adipocyte and enzyme-specific transcription factors as well as genes that modulate mitochondrial function. Resveratrol also increases the processes of lipolysis and reduces lipogenesis in mature adipocytes [<xref rid="B50" ref-type="bibr">50</xref>].</p><p>In this study, following a 12-month administration of resveratrol 100&#x02009;mg and 200&#x02009;mg, respectively, there was a significant decrease in mean BMI when compared to the control group, with no significant differences between the groups with 100 and 200&#x02009;mg. BMI values have changed over the 12 months even though most patients kept their weight, the results showing a decrease of this index.</p><p>Dyslipidemia and steatohepatitis determined by the atherogenic diet in mice were improved by resveratrol, its beneficial effects being correlated with the altered expression of hepatic genes implicated in lipid metabolism [<xref rid="B51" ref-type="bibr">51</xref>]. In obese mice, given a high-calorie diet, resveratrol significantly decreased the body weight [<xref rid="B52" ref-type="bibr">52</xref>&#x02013;<xref rid="B54" ref-type="bibr">54</xref>]. Studies on the nonhuman primate (<italic>Microcebus murinus)</italic> found that the administration of 200&#x02009;mg/kg/day of resveratrol caused an increase in basal metabolism and energy consumption, suggesting a potential mechanism for weight loss [<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>]. In this paper, favorable changes in the lipid profile in all three groups, both at 6 months and at 12 months, may be associated with the hygienic-dietary regimen imposed on poststroke patients.</p><p>Six months after starting resveratrol administration, a significant decrease in cholesterol and lipid profile change in favor of the patient was observed. Significant values in lipid profile changes were even more noticeable 12 months after resveratrol administration started. In order to define the lipid profile, a great importance had the increase in HDL cholesterol values and decrease in LDL cholesterol, respectively, after the administration of resveratrol. Triglyceride levels decreased significantly in the groups of patients with resveratrol. Between the two resveratrol groups, there were significant differences in triglyceride values, which meaningfully decreased in the group with 200&#x02009;mg/day/patient.</p><p>In the literature, it has been highlighted that resveratrol has antidiabetic effects, with a positive effect on both insulin and pancreatic <italic>&#x003b2;</italic> cells, and impedes complications of the disease [<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>]. Resveratrol activates the Sirtuin 1 (SIRT1) pathways, according to some recent studies on how resveratrol works in diabetes. SIRT1 expression and activity were significantly reduced in experimental models of diabetes mellitus. Some of the favorable effects of resveratrol on adjusting glucose homeostasis are mediated by the activation of adenosine monophosphate-activated kinase (AMPK). Modification of AMPK activity, under hyperglycemic conditions, correlates with insulin resistance and tissue damage and with hyperglycemia, supporting a key role of AMPK in type 2 diabetes [<xref rid="B59" ref-type="bibr">59</xref>].</p><p>Data existing in the literature show diverse effective doses of resveratrol in insulin-resistant individuals. Thus, it is important to understand that the mechanisms of action of resveratrol can vary according to its dose. Treatment with lower doses of resveratrol activates SIRT1, while higher doses activate AMPK in a way independent of SIRT1 [<xref rid="B60" ref-type="bibr">60</xref>].</p><p>We noticed a decrease in blood glucose levels, both in the first and last six months of administration. The changes were not significant in diabetic patients for none of the studied groups; however, the effect was more favorable in the resveratrol groups. Oxidative stress plays an important role in the development of insulin resistance and can be neutralized by the antioxidant effect of resveratrol [<xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B61" ref-type="bibr">61</xref>]. Previous studies indicated increased insulin sensitivity in patients treated with resveratrol [<xref rid="B62" ref-type="bibr">62</xref>] and explained these effects by the decrease in oxidative stress, as evidenced by the monitoring of some biochemical parameters.</p><p>Recommendations: six months after starting resveratrol administration, a significant decrease in cholesterol and LDL cholesterol was observed. Thus, adding resveratrol to standard lipid-lowering medication may help restoring normal lipid profile values in these patients (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Observation of the lifestyle and nutrition subsequent to a stroke of a patient was not an objective in itself of our study but could be a direction for further research.</p></sec><sec id="sec5"><title>5. Conclusions</title><p>The supplementation of allopathic treatment with resveratrol had a beneficial effect on all monitored parameters that serve as major risk factors for stroke. The response to treatment was better in the 200&#x02009;mg resveratrol group, but the differences were not significant compared to the 100&#x02009;mg resveratrol group. Therefore, resveratrol can be used as a complementary, long-term therapy, as well as a beneficial adjuvant in the secondary prevention of stroke.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BMI:</term><def><p>Body mass index</p></def></def-item><def-item><term>BP:</term><def><p>Blood pressure</p></def></def-item><def-item><term>DNA:</term><def><p>Deoxyribonucleic acid</p></def></def-item><def-item><term>ES:</term><def><p>Effect size</p></def></def-item><def-item><term>HbA1c:</term><def><p>Glycosylated hemoglobin</p></def></def-item><def-item><term>HDL:</term><def><p>High-density lipoprotein</p></def></def-item><def-item><term>LDL:</term><def><p>Low-density lipoprotein</p></def></def-item><def-item><term>ROS:</term><def><p>Reactive oxygen species</p></def></def-item><def-item><term>SIRT1:</term><def><p>Sirtuin 1</p></def></def-item><def-item><term>AMPK:</term><def><p>Adenosine monophosphate-activated kinase.</p></def></def-item></def-list></glossary><sec><title>Conflicts of Interest</title><p>The authors declare that they have no conflicts of interest.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Loukianoff</surname><given-names>H. D.</given-names></name><name><surname>McLaughlin</surname><given-names>S. L.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Sen</surname><given-names>C. K. L.</given-names></name><name><surname>Pacher</surname><given-names>O.</given-names></name></person-group><source><italic>Oxidative Stress Indices: Analytical Aspects and Significance in Handbook of Oxidants and Antioxidants in Exercise</italic></source><year>2000</year><publisher-loc>Amsterdam</publisher-loc><publisher-name>Elsevier</publisher-name></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dr&#x000f6;ge</surname><given-names>W.</given-names></name></person-group><article-title>Free radicals in the physiological control of cell function</article-title><source><italic>Physiological Reviews</italic></source><year>2002</year><volume>82</volume><issue>1</issue><fpage>47</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1152/physrev.00018.2001</pub-id><pub-id pub-id-type="other">2-s2.0-0036086130</pub-id><pub-id pub-id-type="pmid">11773609</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>D. P.</given-names></name></person-group><article-title>Redefining oxidative stress</article-title><source><italic>Antioxidants &#x00026; Redox Signaling</italic></source><year>2006</year><volume>8</volume><issue>9-10</issue><fpage>1865</fpage><lpage>1879</lpage><pub-id pub-id-type="doi">10.1089/ars.2006.8.1865</pub-id><pub-id pub-id-type="other">2-s2.0-33744962865</pub-id><pub-id pub-id-type="pmid">16987039</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaffer</surname><given-names>H.</given-names></name><name><surname>Morris</surname><given-names>V. B.</given-names></name><name><surname>Stewart</surname><given-names>D.</given-names></name><name><surname>Labhasetwar</surname><given-names>V.</given-names></name></person-group><article-title>Advances in stroke therapy</article-title><source><italic>Drug Delivery and Translational Research</italic></source><year>2011</year><volume>1</volume><issue>6</issue><fpage>409</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1007/s13346-011-0046-y</pub-id><pub-id pub-id-type="other">2-s2.0-84861227467</pub-id><pub-id pub-id-type="pmid">22201014</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>M. J.</given-names></name><name><surname>Xavier</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the Interstroke study): a case-control study</article-title><source><italic>Lancet</italic></source><year>2010</year><volume>376</volume><issue>9735</issue><fpage>112</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60834-3</pub-id><pub-id pub-id-type="other">2-s2.0-77955014011</pub-id><pub-id pub-id-type="pmid">20561675</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valko</surname><given-names>M.</given-names></name><name><surname>Leibfritz</surname><given-names>D.</given-names></name><name><surname>Moncol</surname><given-names>J.</given-names></name><name><surname>Cronin</surname><given-names>M. T. D.</given-names></name><name><surname>Mazur</surname><given-names>M.</given-names></name><name><surname>Telser</surname><given-names>J.</given-names></name></person-group><article-title>Free radicals and antioxidants in normal physiological functions and human disease</article-title><source><italic>The International Journal of Biochemistry &#x00026; Cell Biology</italic></source><year>2007</year><volume>39</volume><issue>1</issue><fpage>44</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2006.07.001</pub-id><pub-id pub-id-type="other">2-s2.0-33749986298</pub-id><pub-id pub-id-type="pmid">16978905</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>D.</given-names></name><name><surname>Griendling</surname><given-names>K. K.</given-names></name><name><surname>Landmesser</surname><given-names>U.</given-names></name><name><surname>Hornig</surname><given-names>B.</given-names></name><name><surname>Drexler</surname><given-names>H.</given-names></name></person-group><article-title>Role of oxidative stress in atherosclerosis</article-title><source><italic>American Journal of Cardiology</italic></source><year>2003</year><volume>91</volume><issue>3</issue><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(02)03144-2</pub-id><pub-id pub-id-type="other">2-s2.0-0037421492</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janardhan</surname><given-names>V.</given-names></name><name><surname>Qureshi</surname><given-names>A. I.</given-names></name></person-group><article-title>Mechanisms of ischemic brain injury</article-title><source><italic>Current Cardiology Reports</italic></source><year>2004</year><volume>6</volume><issue>2</issue><fpage>117</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1007/s11886-004-0009-8</pub-id><pub-id pub-id-type="other">2-s2.0-2442699345</pub-id><pub-id pub-id-type="pmid">14759356</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname><given-names>J. J.</given-names></name></person-group><article-title>Redox regulation of pro-inflammatory cytokines and IkappaB-&#x003b1;/NF-&#x003ba;B nuclear translocation and activation</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2002</year><volume>296</volume><issue>4</issue><fpage>847</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(02)00947-6</pub-id><pub-id pub-id-type="other">2-s2.0-0036384284</pub-id><pub-id pub-id-type="pmid">12200125</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>R. A.</given-names></name><name><surname>Laskin</surname><given-names>D. L.</given-names></name><name><surname>Smith</surname><given-names>C. V.</given-names></name><etal/></person-group><article-title>Nitrative and oxidative stress in toxicology and disease</article-title><source><italic>Toxicological Sciences</italic></source><year>2009</year><volume>112</volume><issue>1</issue><fpage>4</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfp179</pub-id><pub-id pub-id-type="other">2-s2.0-71049194727</pub-id><pub-id pub-id-type="pmid">19656995</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finkel</surname><given-names>T.</given-names></name><name><surname>Holbrook</surname><given-names>N. J.</given-names></name></person-group><article-title>Oxidants, oxidative stress and the biology of ageing</article-title><source><italic>Nature</italic></source><year>2000</year><volume>408</volume><issue>6809</issue><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1038/35041687</pub-id><pub-id pub-id-type="other">2-s2.0-0034626735</pub-id><pub-id pub-id-type="pmid">11089981</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Copolovici</surname><given-names>D.</given-names></name><name><surname>Bungau</surname><given-names>S.</given-names></name><name><surname>Boscencu</surname><given-names>R.</given-names></name><name><surname>Tit</surname><given-names>D. M.</given-names></name><name><surname>Copolovici</surname><given-names>L.</given-names></name></person-group><article-title>The fatty acids composition and antioxidant activity of walnut cold press oil</article-title><source><italic>Revista de Chimie - Bucharest</italic></source><year>2017</year><volume>68</volume><issue>3</issue><fpage>507</fpage><lpage>509</lpage></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Carney</surname><given-names>J. M.</given-names></name><name><surname>Duchon</surname><given-names>A.</given-names></name><name><surname>Floyd</surname><given-names>R. A.</given-names></name><name><surname>Chevion</surname><given-names>M.</given-names></name></person-group><article-title>Oxygen free radical involvement in ischemia and reperfusion injury to brain</article-title><source><italic>Neuroscience Letters</italic></source><year>1988</year><volume>88</volume><issue>2</issue><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(88)90132-2</pub-id><pub-id pub-id-type="other">2-s2.0-0023887866</pub-id><pub-id pub-id-type="pmid">3380359</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalogeris</surname><given-names>T.</given-names></name><name><surname>Bao</surname><given-names>Y.</given-names></name><name><surname>Korthuis</surname><given-names>R. J.</given-names></name></person-group><article-title>Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning</article-title><source><italic>Redox Biology</italic></source><year>2014</year><volume>2</volume><fpage>702</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2014.05.006</pub-id><pub-id pub-id-type="other">2-s2.0-84902322007</pub-id><pub-id pub-id-type="pmid">24944913</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>C. L.</given-names></name><name><surname>Bayraktutan</surname><given-names>U.</given-names></name></person-group><article-title>Oxidative stress and its role in the pathogenesis of ischaemic stroke</article-title><source><italic>International Journal of Stroke</italic></source><year>2009</year><volume>4</volume><issue>6</issue><fpage>461</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1111/j.1747-4949.2009.00387.x</pub-id><pub-id pub-id-type="other">2-s2.0-77449152992</pub-id><pub-id pub-id-type="pmid">19930058</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneto</surname><given-names>H.</given-names></name><name><surname>Katakami</surname><given-names>N.</given-names></name><name><surname>Matsuhisa</surname><given-names>M.</given-names></name><name><surname>Matsuoka</surname><given-names>T. A.</given-names></name></person-group><article-title>Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis</article-title><source><italic>Mediators of Inflammation</italic></source><year>2010</year><volume>2010</volume><fpage>11</fpage><pub-id pub-id-type="publisher-id">453892</pub-id><pub-id pub-id-type="doi">10.1155/2010/453892</pub-id><pub-id pub-id-type="other">2-s2.0-77952480033</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urso</surname><given-names>M. L.</given-names></name><name><surname>Clarkson</surname><given-names>P. M.</given-names></name></person-group><article-title>Oxidative stress, exercise, and antioxidant supplementation</article-title><source><italic>Toxicology</italic></source><year>2003</year><volume>189</volume><issue>1-2</issue><fpage>41</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/S0300-483X(03)00151-3</pub-id><pub-id pub-id-type="other">2-s2.0-0038342017</pub-id><pub-id pub-id-type="pmid">12821281</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>V.</given-names></name><name><surname>Patel</surname><given-names>K.</given-names></name><name><surname>Viskaduraki</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis</article-title><source><italic>Cancer Research</italic></source><year>2010</year><volume>70</volume><issue>22</issue><fpage>9003</fpage><lpage>9011</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2364</pub-id><pub-id pub-id-type="other">2-s2.0-78549288940</pub-id><pub-id pub-id-type="pmid">20935227</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherubini</surname><given-names>A.</given-names></name><name><surname>Ruggiero</surname><given-names>C.</given-names></name><name><surname>Morand</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Dietary antioxidants as potential pharmacological agents for ischemic stroke</article-title><source><italic>Current Medicinal Chemistry</italic></source><year>2008</year><volume>15</volume><issue>12</issue><fpage>1236</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.2174/092986708784310431</pub-id><pub-id pub-id-type="other">2-s2.0-45849148473</pub-id><pub-id pub-id-type="pmid">18473816</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smoliga</surname><given-names>J. M.</given-names></name><name><surname>Baur</surname><given-names>J. A.</given-names></name><name><surname>Hausenblas</surname><given-names>H. A.</given-names></name></person-group><article-title>Resveratrol and health&#x02014;a comprehensive review of human clinical trials</article-title><source><italic>Molecular Nutrition &#x00026; Food Research</italic></source><year>2011</year><volume>55</volume><issue>8</issue><fpage>1129</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1002/mnfr.201100143</pub-id><pub-id pub-id-type="other">2-s2.0-79961047423</pub-id><pub-id pub-id-type="pmid">21688389</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagchi</surname><given-names>D.</given-names></name><name><surname>Das</surname><given-names>D. K.</given-names></name><name><surname>Tosaki</surname><given-names>A.</given-names></name><name><surname>Bagchi</surname><given-names>M.</given-names></name><name><surname>Kothari</surname><given-names>S. C.</given-names></name></person-group><article-title>Benefits of resveratrol in women&#x02019;s health</article-title><source><italic>Drugs under Experimental and Clinical Research</italic></source><year>2001</year><volume>27</volume><issue>5-6</issue><fpage>233</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">11951581</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>J.</given-names></name><name><surname>Yokota</surname><given-names>T.</given-names></name><name><surname>Ashihara</surname><given-names>H.</given-names></name><name><surname>Lean</surname><given-names>M. E. J.</given-names></name><name><surname>Crozier</surname><given-names>A.</given-names></name></person-group><article-title>Plant foods and herbal sources of resveratrol</article-title><source><italic>Food Chemistry</italic></source><year>2002</year><volume>50</volume><issue>11</issue><fpage>3337</fpage><lpage>3340</lpage><pub-id pub-id-type="doi">10.1021/jf0112973</pub-id><pub-id pub-id-type="other">2-s2.0-0037157069</pub-id><pub-id pub-id-type="pmid">12010007</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>T. L.</given-names></name><name><surname>Wang</surname><given-names>X. H.</given-names></name><name><surname>Pazmino</surname><given-names>J.</given-names></name><name><surname>Engeseth</surname><given-names>N. J.</given-names></name></person-group><article-title>Antioxidant capacity and phenolic content of grapes, sun-dried raisins, and golden raisinsand their effect on ex vivo serum antioxidant capacity</article-title><source><italic>Journal of Agricultural and Food Chemistry</italic></source><year>2007</year><volume>55</volume><issue>21</issue><fpage>8472</fpage><lpage>8477</lpage><pub-id pub-id-type="doi">10.1021/jf071468p</pub-id><pub-id pub-id-type="other">2-s2.0-35548966192</pub-id><pub-id pub-id-type="pmid">17880162</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Soares</surname><given-names>R.</given-names></name><name><surname>Costa</surname><given-names>C.</given-names></name></person-group><source><italic>Oxidative Stress, Inflammations and Angiogenesis in the Metabolic Syndrome</italic></source><year>2009</year><publisher-loc>Netherlands</publisher-loc><publisher-name>Springer</publisher-name></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brisdelli</surname><given-names>F.</given-names></name><name><surname>D'Andrea</surname><given-names>G.</given-names></name><name><surname>Bozzi</surname><given-names>A.</given-names></name></person-group><article-title>Resveratrol: a natural polyphenol with multiple chemopreventive properties</article-title><source><italic>Current Drug Metabolism</italic></source><year>2009</year><volume>10</volume><issue>6</issue><fpage>530</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.2174/138920009789375423</pub-id><pub-id pub-id-type="other">2-s2.0-70450123699</pub-id><pub-id pub-id-type="pmid">19702538</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>K. R.</given-names></name><name><surname>Scott</surname><given-names>E.</given-names></name><name><surname>Brown</surname><given-names>V. A.</given-names></name><name><surname>Gescher</surname><given-names>A. J.</given-names></name><name><surname>Steward</surname><given-names>W. P.</given-names></name><name><surname>Brown</surname><given-names>K.</given-names></name></person-group><article-title>Clinical trials of resveratrol</article-title><source><italic>Annals of the New York Academy of Sciences</italic></source><year>2011</year><volume>1215</volume><issue>1</issue><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05853.x</pub-id><pub-id pub-id-type="other">2-s2.0-78851472303</pub-id><pub-id pub-id-type="pmid">21261655</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G.</given-names></name><name><surname>De Backer</surname><given-names>G.</given-names></name><name><surname>Dominiczak</surname><given-names>A.</given-names></name><etal/></person-group><article-title>2007 guidelines for the management of arterial hypertension, the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</article-title><source><italic>Journal of Hypertension</italic></source><year>2007</year><volume>25</volume><issue>6</issue><fpage>1105</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1097/hjh.0b013e3281fc975a</pub-id><pub-id pub-id-type="other">2-s2.0-34250350040</pub-id><pub-id pub-id-type="pmid">17563527</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="other"><collab>WHO/Europe</collab><source><italic>Body Mass Index&#x02014;BMI</italic></source><comment><ext-link ext-link-type="uri" xlink:href="http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi">http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi</ext-link></comment></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="other"><collab>American Diabetes Association (ADA) 2016 Guideline</collab><source><italic>Diabetes Management Guidelines</italic></source><comment><ext-link ext-link-type="uri" xlink:href="http://www.ndei.org/ADA-diabetes-management-guidelines-in-patient-glycemia-targets-critically-ill.aspx.html">http://www.ndei.org/ADA-diabetes-management-guidelines-in-patient-glycemia-targets-critically-ill.aspx.html</ext-link></comment></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>G. M.</given-names></name><name><surname>Feinn</surname><given-names>R.</given-names></name></person-group><article-title>Using effect size&#x02014;or why the <italic>P-value</italic> is not enough</article-title><source><italic>Journal of Graduate Medical Education</italic></source><year>2012</year><volume>4</volume><issue>3</issue><fpage>279</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.4300/JGME-D-12-00156.1</pub-id><pub-id pub-id-type="pmid">23997866</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bumbu</surname><given-names>A.</given-names></name><name><surname>Pasca</surname><given-names>B.</given-names></name><name><surname>Tit</surname><given-names>D. M.</given-names></name><name><surname>Bungau</surname><given-names>S.</given-names></name><name><surname>Bumbu</surname><given-names>G.</given-names></name></person-group><article-title>The effects of soy isoflavones and hormonal replacing therapy on the incidence and evolution of postmenopausal female urinary incontinence</article-title><source><italic>Farmacia</italic></source><year>2016</year><volume>64</volume><issue>3</issue><fpage>419</fpage><lpage>424</lpage></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrizzo</surname><given-names>A.</given-names></name><name><surname>Puca</surname><given-names>A.</given-names></name><name><surname>Damato</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Resveratrol improves vascular function in patients with hypertension and dyslipidemia by modulating NO metabolism</article-title><source><italic>Hypertension</italic></source><year>2013</year><volume>62</volume><issue>2</issue><fpage>359</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.111.01009</pub-id><pub-id pub-id-type="other">2-s2.0-84880951858</pub-id><pub-id pub-id-type="pmid">23753407</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>M. M.</given-names></name><name><surname>Byrne</surname><given-names>N. J.</given-names></name><name><surname>Robertson</surname><given-names>I. M.</given-names></name><etal/></person-group><article-title>Resveratrol improves exercise performance and skeletal muscle oxidative capacity in heart failure</article-title><source><italic>American Journal of Physiology Heart and Circulatory Physiology</italic></source><year>2017</year><volume>312</volume><issue>4</issue><fpage>H842</fpage><lpage>H853</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00455.2016</pub-id><pub-id pub-id-type="other">2-s2.0-85017295771</pub-id><pub-id pub-id-type="pmid">28159807</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cottart</surname><given-names>C. H.</given-names></name><name><surname>Nivet-Antoine</surname><given-names>V.</given-names></name><name><surname>Beaudeux</surname><given-names>J. L.</given-names></name></person-group><article-title>Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans</article-title><source><italic>Molecular Nutrition &#x00026; Food Research</italic></source><year>2014</year><volume>58</volume><issue>1</issue><fpage>7</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1002/mnfr.201200589</pub-id><pub-id pub-id-type="other">2-s2.0-84886015444</pub-id><pub-id pub-id-type="pmid">23740855</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>L. M.</given-names></name><name><surname>Chen</surname><given-names>J. K.</given-names></name><name><surname>Huang</surname><given-names>S. S.</given-names></name><name><surname>Lee</surname><given-names>R. S.</given-names></name><name><surname>Su</surname><given-names>M. J.</given-names></name></person-group><article-title>Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes</article-title><source><italic>Cardiovascular Research</italic></source><year>2000</year><volume>47</volume><issue>3</issue><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/s0008-6363(00)00102-4</pub-id><pub-id pub-id-type="other">2-s2.0-0034682983</pub-id><pub-id pub-id-type="pmid">10963727</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Zorita</surname><given-names>S.</given-names></name><name><surname>Fernandez-Quintela</surname><given-names>A.</given-names></name><name><surname>Lasa</surname><given-names>A.</given-names></name><name><surname>Hijona</surname><given-names>E.</given-names></name><name><surname>Bujanda</surname><given-names>L.</given-names></name><name><surname>Portillo</surname><given-names>M. P.</given-names></name></person-group><article-title>Effects of resveratrol on obesity-related inflammation markers in adipose tissue of genetically obese rats</article-title><source><italic>Nutrition</italic></source><year>2013</year><volume>29</volume><issue>11-12</issue><fpage>1374</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2013.04.014</pub-id><pub-id pub-id-type="other">2-s2.0-84884987767</pub-id><pub-id pub-id-type="pmid">24012391</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ljubicic</surname><given-names>V.</given-names></name><name><surname>Burt</surname><given-names>M.</given-names></name><name><surname>Lunde</surname><given-names>J. A.</given-names></name><name><surname>Jasmin</surname><given-names>B. J.</given-names></name></person-group><article-title>Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1<italic>&#x003b1;</italic>axis</article-title><source><italic>American Journal of Physiology-Cell Physiology</italic></source><year>2014</year><volume>307</volume><issue>1</issue><fpage>C66</fpage><lpage>C82</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00357.2013</pub-id><pub-id pub-id-type="other">2-s2.0-84903625199</pub-id><pub-id pub-id-type="pmid">24760981</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashid</surname><given-names>P.</given-names></name><name><surname>Leonardi-Bee</surname><given-names>J.</given-names></name><name><surname>Bath</surname><given-names>P.</given-names></name></person-group><article-title>Blood pressure reduction and secondary prevention of stroke and other vascular events, a systematic review</article-title><source><italic>Stroke</italic></source><year>2003</year><volume>34</volume><issue>11</issue><fpage>2741</fpage><lpage>2748</lpage><pub-id pub-id-type="doi">10.1161/01.STR.0000092488.40085.15</pub-id><pub-id pub-id-type="other">2-s2.0-0242694033</pub-id><pub-id pub-id-type="pmid">14576382</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flemming</surname><given-names>K. D.</given-names></name><name><surname>Brown</surname><given-names>R.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Secondary prevention strategies in ischemic stroke: identification and optimal management of modifiable risk factors</article-title><source><italic>Mayo Clinic Proceedings</italic></source><year>2004</year><volume>79</volume><issue>10</issue><fpage>1330</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.4065/79.10.1330</pub-id><pub-id pub-id-type="other">2-s2.0-4644241899</pub-id><pub-id pub-id-type="pmid">15473419</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierra</surname><given-names>C.</given-names></name><name><surname>Coca</surname><given-names>A.</given-names></name><name><surname>Schiffrin</surname><given-names>E. L.</given-names></name></person-group><article-title>Vascular mechanisms in the pathogenesis of stroke</article-title><source><italic>Current Hypertension Reports</italic></source><year>2011</year><volume>13</volume><issue>3</issue><fpage>200</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1007/s11906-011-0195-x</pub-id><pub-id pub-id-type="other">2-s2.0-79956203683</pub-id><pub-id pub-id-type="pmid">21331606</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacher</surname><given-names>P.</given-names></name><name><surname>Beckman</surname><given-names>J. S.</given-names></name><name><surname>Liaudet</surname><given-names>L.</given-names></name></person-group><article-title>Nitric oxide and peroxynitrite in health and disease</article-title><source><italic>Physiological Reviews</italic></source><year>2007</year><volume>87</volume><issue>1</issue><fpage>315</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1152/physrev.00029.2006</pub-id><pub-id pub-id-type="other">2-s2.0-33846863589</pub-id><pub-id pub-id-type="pmid">17237348</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Touyz</surname><given-names>R. M.</given-names></name><name><surname>Schiffrin</surname><given-names>E. L.</given-names></name></person-group><article-title>Reactive oxygen species in vascular biology: implications in hypertension</article-title><source><italic>Histochemistry and Cell Biology</italic></source><year>2004</year><volume>122</volume><issue>4</issue><fpage>339</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1007/s00418-004-0696-7</pub-id><pub-id pub-id-type="other">2-s2.0-8644277006</pub-id><pub-id pub-id-type="pmid">15338229</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czernichow</surname><given-names>S.</given-names></name><name><surname>Blacher</surname><given-names>J.</given-names></name><name><surname>Hercberg</surname><given-names>S.</given-names></name></person-group><article-title>Antioxidant vitamins and blood pressure</article-title><source><italic>Current Hypertension Reports</italic></source><year>2004</year><volume>6</volume><issue>1</issue><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s11906-004-0007-7</pub-id><pub-id pub-id-type="other">2-s2.0-5444269460</pub-id><pub-id pub-id-type="pmid">14972086</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fodor</surname><given-names>K.</given-names></name><name><surname>Tit</surname><given-names>D. M.</given-names></name><name><surname>Bungau</surname><given-names>S.</given-names></name><name><surname>Dragan</surname><given-names>F.</given-names></name><name><surname>Gatea</surname><given-names>D.</given-names></name></person-group><article-title>The evaluation of the effectiveness of resveratrol in blood pressure</article-title><source><italic>Annals of Oradea University, Fascicle: Ecotoxicology, Animal Husbandry and Technologies for Food Industry</italic></source><year>2014</year><volume>13</volume><issue>A</issue><fpage>105</fpage><lpage>110</lpage></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>J. H.</given-names></name><name><surname>Ziebland</surname><given-names>S.</given-names></name><name><surname>Yudkin</surname><given-names>P.</given-names></name><name><surname>Roe</surname><given-names>L. S.</given-names></name><name><surname>Neil</surname><given-names>H. A. W.</given-names></name></person-group><article-title>Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial</article-title><source><italic>The Lancet</italic></source><year>2002</year><volume>359</volume><issue>9322</issue><fpage>1969</fpage><lpage>1974</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)98858-6</pub-id><pub-id pub-id-type="other">2-s2.0-0037042466</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baur</surname><given-names>J. A.</given-names></name><name><surname>Sinclair</surname><given-names>D. A.</given-names></name></person-group><article-title>Therapeutic potential of resveratrol: the in vivo evidence</article-title><source><italic>Nature Reviews Drug Discovery</italic></source><year>2006</year><volume>5</volume><issue>6</issue><fpage>493</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1038/nrd2060</pub-id><pub-id pub-id-type="other">2-s2.0-33745962138</pub-id><pub-id pub-id-type="pmid">16732220</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodotou</surname><given-names>M.</given-names></name><name><surname>Fokianos</surname><given-names>K.</given-names></name><name><surname>Mouzouridou</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The effect of resveratrol on hypertension: a clinical trial</article-title><source><italic>Experimental and Therapeutic Medicine</italic></source><year>2017</year><volume>13</volume><issue>1</issue><fpage>295</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.3892/etm.2016.3958</pub-id><pub-id pub-id-type="other">2-s2.0-85005992284</pub-id><pub-id pub-id-type="pmid">28123505</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Luo</surname><given-names>T.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Tang</surname><given-names>Z.</given-names></name></person-group><article-title>Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice</article-title><source><italic>Hypertension Research</italic></source><year>2014</year><volume>37</volume><issue>9</issue><fpage>803</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1038/hr.2014.90</pub-id><pub-id pub-id-type="other">2-s2.0-84906485679</pub-id><pub-id pub-id-type="pmid">24965170</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leiherer</surname><given-names>A.</given-names></name><name><surname>M&#x000fc;ndlein</surname><given-names>A.</given-names></name><name><surname>Drexel</surname><given-names>H.</given-names></name></person-group><article-title>Phytochemicals and their impact on adipose tissue inflammation and diabetes</article-title><source><italic>Vascular Pharmacology</italic></source><year>2013</year><volume>58</volume><issue>1-2</issue><fpage>3</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.vph.2012.09.002</pub-id><pub-id pub-id-type="other">2-s2.0-84871717518</pub-id><pub-id pub-id-type="pmid">22982056</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baile</surname><given-names>C. A.</given-names></name><name><surname>Yang</surname><given-names>J. Y.</given-names></name><name><surname>Rayalam</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Effect of resveratrol on fat mobilization</article-title><source><italic>Annals of the New York Academy of Sciences</italic></source><year>2011</year><volume>1215</volume><issue>1</issue><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05845.x</pub-id><pub-id pub-id-type="other">2-s2.0-78851469588</pub-id><pub-id pub-id-type="pmid">21261640</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>J.</given-names></name><name><surname>Cho</surname><given-names>I.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Kwon</surname><given-names>D.</given-names></name><name><surname>Ha</surname><given-names>T.</given-names></name></person-group><article-title>Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet</article-title><source><italic>Journal of Hepatology</italic></source><year>2008</year><volume>49</volume><issue>6</issue><fpage>1019</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2008.08.012</pub-id><pub-id pub-id-type="other">2-s2.0-55549097087</pub-id><pub-id pub-id-type="pmid">18930334</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagouge</surname><given-names>M.</given-names></name><name><surname>Argmann</surname><given-names>C.</given-names></name><name><surname>Gerhart-Hines</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1<italic>&#x003b1;</italic></article-title><source><italic>Cell</italic></source><year>2006</year><volume>127</volume><issue>6</issue><fpage>1109</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.11.013</pub-id><pub-id pub-id-type="other">2-s2.0-33845399894</pub-id><pub-id pub-id-type="pmid">17112576</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasa</surname><given-names>A.</given-names></name><name><surname>Schweigerb</surname><given-names>M.</given-names></name><name><surname>Kotzbeck</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Resveratrol regulates lipolysis via adipose triglyceride lipase</article-title><source><italic>The Journal of Nutritional Biochemistry</italic></source><year>2012</year><volume>23</volume><issue>4</issue><fpage>379</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2010.12.014</pub-id><pub-id pub-id-type="other">2-s2.0-84858295952</pub-id><pub-id pub-id-type="pmid">21543206</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baur</surname><given-names>J. A.</given-names></name><name><surname>Pearson</surname><given-names>K. J.</given-names></name><name><surname>Price</surname><given-names>N. L.</given-names></name><etal/></person-group><article-title>Resveratrol improves health and survival of mice on a high-calorie diet</article-title><source><italic>Nature</italic></source><year>2006</year><volume>444</volume><issue>7117</issue><fpage>337</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1038/nature05354</pub-id><pub-id pub-id-type="other">2-s2.0-33751072349</pub-id><pub-id pub-id-type="pmid">17086191</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dal-Pan</surname><given-names>A.</given-names></name><name><surname>Terrien</surname><given-names>J.</given-names></name><name><surname>Pifferi</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Caloric restriction or resveratrol supplementation and ageing in a non-human primate: first-year outcome of the RESTRIKAL study in <italic>Microcebus murinus</italic></article-title><source><italic>Age</italic></source><year>2010</year><volume>33</volume><issue>1</issue><fpage>15</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1007/s11357-010-9156-6</pub-id><pub-id pub-id-type="other">2-s2.0-79952537457</pub-id><pub-id pub-id-type="pmid">20532988</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dal-Pan</surname><given-names>A.</given-names></name><name><surname>Blanc</surname><given-names>S.</given-names></name><name><surname>Aujard</surname><given-names>F.</given-names></name></person-group><article-title>Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity</article-title><source><italic>BMC Physiology</italic></source><year>2010</year><volume>10</volume><issue>1</issue><fpage>p. 11</fpage><pub-id pub-id-type="doi">10.1186/1472-6793-10-11</pub-id><pub-id pub-id-type="other">2-s2.0-77953679841</pub-id><pub-id pub-id-type="pmid">20569453</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyenihi</surname><given-names>O. R.</given-names></name><name><surname>Oyenihi</surname><given-names>A. B.</given-names></name><name><surname>Adeyanju</surname><given-names>A. A.</given-names></name><name><surname>Oguntibeju</surname><given-names>O. O.</given-names></name></person-group><article-title>Antidiabetic effects of resveratrol: the way forward in its clinical utility</article-title><source><italic>Journal of Diabetes Research</italic></source><year>2016</year><volume>2016</volume><fpage>14</fpage><pub-id pub-id-type="publisher-id">9737483</pub-id><pub-id pub-id-type="doi">10.1155/2016/9737483</pub-id><pub-id pub-id-type="other">2-s2.0-85008656035</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szkudelski</surname><given-names>T.</given-names></name><name><surname>Szkudelska</surname><given-names>K.</given-names></name></person-group><article-title>Resveratrol and diabetes: from animal to human studies</article-title><source><italic>Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease</italic></source><year>2015</year><volume>1852</volume><issue>6</issue><fpage>1145</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2014.10.013</pub-id><pub-id pub-id-type="other">2-s2.0-84940106420</pub-id><pub-id pub-id-type="pmid">25445538</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>B.</given-names></name><name><surname>Maeda</surname><given-names>N.</given-names></name></person-group><article-title>
<italic>&#x003b1;</italic>- lipoic acid prevents the increase in atherosclerosis induced by diabetes in apolipoprotein E-deficient mice fed high-fat/low-cholesterol diet</article-title><source><italic>Diabetes</italic></source><year>2006</year><volume>55</volume><issue>8</issue><fpage>2238</fpage><lpage>2244</lpage><pub-id pub-id-type="doi">10.2337/db06-0251</pub-id><pub-id pub-id-type="other">2-s2.0-33749363594</pub-id><pub-id pub-id-type="pmid">16873686</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brasnyo</surname><given-names>P.</given-names></name><name><surname>Molnar</surname><given-names>G. A.</given-names></name><name><surname>Mohas</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients</article-title><source><italic>British Journal of Nutrition</italic></source><year>2011</year><volume>106</volume><issue>03</issue><fpage>383</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1017/S0007114511000316</pub-id><pub-id pub-id-type="other">2-s2.0-80052910300</pub-id><pub-id pub-id-type="pmid">21385509</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vang</surname><given-names>O.</given-names></name><name><surname>Das</surname><given-names>D. K.</given-names></name></person-group><article-title>Resveratrol and health</article-title><source><italic>Annals of the New York Academy of Sciences</italic></source><year>2011</year><volume>1215</volume><issue>8</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21261635</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>N. L.</given-names></name><name><surname>Gomes</surname><given-names>A. P.</given-names></name><name><surname>Ling</surname><given-names>A. J.</given-names></name><etal/></person-group><article-title>SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function</article-title><source><italic>Cell Metabolism</italic></source><year>2012</year><volume>15</volume><issue>5</issue><fpage>675</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2012.04.003</pub-id><pub-id pub-id-type="other">2-s2.0-84860477354</pub-id><pub-id pub-id-type="pmid">22560220</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><graphic xlink:href="OMCL2018-4147320.001"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and clinical characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Characteristics</th><th align="center" colspan="2" rowspan="1">Resveratrol 100&#x02009;mg group<break/>(<italic>n</italic> = 81)</th><th align="center" colspan="2" rowspan="1">Resveratrol 200&#x02009;mg group<break/>(<italic>n</italic> = 55)</th><th align="center" colspan="2" rowspan="1">Control group<break/>(<italic>n</italic> = 92)</th></tr><tr><th align="center" rowspan="1" colspan="1">Number</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Number</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Number</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">
<italic>Gender</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Females</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">39.51</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">38.18</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">40.22</td></tr><tr><td align="left" rowspan="1" colspan="1">Males</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">60.49</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">61.82</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">59.78</td></tr><tr><td align="left" colspan="7" rowspan="1">
<italic>Age</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">55&#x02013;60 years</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">4.94</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3.63</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5.43</td></tr><tr><td align="left" rowspan="1" colspan="1">61&#x02013;65 years</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">66.67</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">63.64</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">64.13</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;65 years</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">28.39</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">32.73</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">30.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Average</td><td align="center" colspan="2" rowspan="1">
<bold>65.03&#x02009;&#x000b1;&#x02009;8.24</bold>
</td><td align="center" colspan="2" rowspan="1">
<bold>64.52&#x02009;&#x000b1;&#x02009;8.05</bold>
</td><td align="center" colspan="2" rowspan="1">
<bold>64.78&#x02009;&#x000b1;&#x02009;6.32</bold>
</td></tr><tr><td align="left" colspan="7" rowspan="1">
<italic>Risk factors</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Obesity</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">38.27</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">38.18</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">42.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Toxicants (coffee, tobacco, and alcohol)</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">45.68</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">41.82</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">45.65</td></tr><tr><td align="left" rowspan="1" colspan="1">Stress</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">50.62</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">52.73</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">51.09</td></tr><tr><td align="left" rowspan="1" colspan="1">HBP</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">79.01</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">78.18</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">78.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">14.63</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">16.36</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">15.22</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">61.73</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">67.3</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">66.30</td></tr><tr><td align="left" colspan="7" rowspan="1">
<italic>Diagnostic</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ischemic stroke</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">72.64</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">74.54</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">73.91</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemorrhagic stroke</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">27.16</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">25.46</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">26.09</td></tr><tr><td align="left" colspan="7" rowspan="1">
<italic>Time since stroke occurred</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;3 months</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">12.35</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">12.73</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">11.96</td></tr><tr><td align="left" rowspan="1" colspan="1">3&#x02013;6 months</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">56.79</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">54.54</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">54.35</td></tr><tr><td align="left" rowspan="1" colspan="1">6&#x02013;12 months</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">30.86</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">32.73</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">33.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Average (months)</td><td align="center" colspan="2" rowspan="1">
<bold>5.08&#x02009;&#x000b1;&#x02009;1.22</bold>
</td><td align="center" colspan="2" rowspan="1">
<bold>5.13&#x02009;&#x000b1;&#x02009;1.14</bold>
</td><td align="center" colspan="2" rowspan="1">
<bold>5.17&#x02009;&#x000b1;&#x02009;1.16</bold>
</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Effect of resveratrol on blood pressure.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Evaluation</th><th align="center" colspan="4" rowspan="1">BP (mmHg)</th></tr><tr><th align="center" rowspan="1" colspan="1">Systolic BP</th><th align="center" rowspan="1" colspan="1">ES</th><th align="center" rowspan="1" colspan="1">Diastolic BP</th><th align="center" rowspan="1" colspan="1">ES</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">
<italic>Resveratrol 100&#x02009;mg group</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial</td><td align="center" rowspan="1" colspan="1">148.02&#x000a0;&#x000b1;&#x000a0;15.28</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">88.29&#x000a0;&#x000b1;&#x000a0;10.73</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">At 6 months</td><td align="center" rowspan="1" colspan="1">143.12&#x000a0;&#x000b1;&#x000a0;15.16<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">0.32</td><td align="center" rowspan="1" colspan="1">85.89&#x000a0;&#x000b1;&#x000a0;10.22</td><td align="center" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">At 12 months</td><td align="center" rowspan="1" colspan="1">139.85&#x000a0;&#x000b1;&#x000a0;14.82<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.22</td><td align="center" rowspan="1" colspan="1">84.27&#x000a0;&#x000b1;&#x000a0;10.18<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" colspan="5" rowspan="1">
<italic>Resveratrol 200&#x02009;mg group</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial</td><td align="center" rowspan="1" colspan="1">149.21&#x000a0;&#x000b1;&#x000a0;15.13</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">88.47&#x000a0;&#x000b1;&#x000a0;11.11</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">At 6 months</td><td align="center" rowspan="1" colspan="1">142.02&#x000a0;&#x000b1;&#x000a0;15.27<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">85.91&#x000a0;&#x000b1;&#x000a0;11.02</td><td align="center" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">At 12 months</td><td align="center" rowspan="1" colspan="1">139.35&#x000a0;&#x000b1;&#x000a0;14.81<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.17</td><td align="center" rowspan="1" colspan="1">84.10&#x000a0;&#x000b1;&#x000a0;10.78<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" colspan="5" rowspan="1">
<italic>Control group</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial</td><td align="center" rowspan="1" colspan="1">148.42&#x000a0;&#x000b1;&#x000a0;15.22</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">87.61&#x000a0;&#x000b1;&#x000a0;11.25</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">At 6 months</td><td align="center" rowspan="1" colspan="1">146.10&#x000a0;&#x000b1;&#x000a0;15.17</td><td align="center" rowspan="1" colspan="1">0.16</td><td align="center" rowspan="1" colspan="1">86.39&#x000a0;&#x000b1;&#x000a0;11.32</td><td align="center" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">At 12 months</td><td align="center" rowspan="1" colspan="1">145.32&#x000a0;&#x000b1;&#x000a0;15.25</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">85.67&#x000a0;&#x000b1;&#x000a0;11.11</td><td align="center" rowspan="1" colspan="1">0.06</td></tr></tbody></table><table-wrap-foot><fn><p>Values are represented as mean&#x02009;&#x000b1;&#x02009;SD (<italic>n</italic> = 81 patients in the resveratrol 100&#x02009;mg group; <italic>n</italic> = 55 patients in the resveratrol 200&#x02009;mg group; and <italic>n</italic> = 92 patients in the control group); <sup>&#x02217;</sup><italic>p</italic> &#x0003c; 0.05 versus initial value; <sup>c</sup>&#x0003c;0.05 versus control group value.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Effect of resveratrol on the weight status and on the body mass index.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Weight status</th><th align="center" colspan="2" rowspan="1">Resveratrol 100&#x02009;mg group</th><th align="center" colspan="2" rowspan="1">Resveratrol 200&#x02009;mg group</th><th align="center" colspan="2" rowspan="1">Control group</th></tr><tr><th align="center" rowspan="1" colspan="1">Number of patients</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Number of patients</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Number of patients</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Normal weight</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">20.99</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">20.00</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">18.48</td></tr><tr><td align="left" rowspan="1" colspan="1">Overweight</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">40.74</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">41.82</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">39.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Class I obesity</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">22.22</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">21.82</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">23.91</td></tr><tr><td align="left" rowspan="1" colspan="1">Class II obesity</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">11.11</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">12.73</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">13.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Class III obesity</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">4.94</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3.64</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5.43</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI average (initial)</td><td align="center" colspan="2" rowspan="1">
<bold>29.47&#x02009;&#x000b1;&#x02009;4.26</bold>
</td><td align="center" colspan="2" rowspan="1">
<bold>29.50&#x02009;&#x000b1;&#x02009;4.27</bold>
</td><td align="center" colspan="2" rowspan="1">
<bold>29.95&#x02009;&#x000b1;&#x02009;4.49</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal weight</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">25.93</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">27.27</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">18.48</td></tr><tr><td align="left" rowspan="1" colspan="1">Overweight</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">40.74</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">43.64</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">39.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Class I obesity</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">19.75</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">16.36</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">25.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Class II obesity</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">9.88</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">9.09</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">11.96</td></tr><tr><td align="left" rowspan="1" colspan="1">Class II obesity</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3.70</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3.64</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5.43</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI average (at six months)</td><td align="center" colspan="2" rowspan="1">
<bold>27.97&#x02009;&#x000b1;&#x02009;4.44</bold>
<sup>c</sup>
</td><td align="center" colspan="2" rowspan="1">
<bold>27.56&#x02009;&#x000b1;&#x02009;4.28</bold>
<sup>c</sup>
</td><td align="center" colspan="2" rowspan="1">
<bold>29.42&#x02009;&#x000b1;&#x02009;4.72</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ES</td><td align="center" colspan="2" rowspan="1">0.35</td><td align="center" colspan="2" rowspan="1">0.45</td><td align="center" colspan="2" rowspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal weight</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">34.57</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">34.55</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">19.57</td></tr><tr><td align="left" rowspan="1" colspan="1">Overweight</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">44.44</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">45.45</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">39.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Class I obesity</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">12.35</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">10.91</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">23.91</td></tr><tr><td align="left" rowspan="1" colspan="1">Class II obesity</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">6.17</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">7.27</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">11.96</td></tr><tr><td align="left" rowspan="1" colspan="1">Class III obesity</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2.47</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1.82</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5.43</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI average (at 12 months)</td><td align="center" colspan="2" rowspan="1">
<bold>26.75&#x02009;&#x000b1;&#x02009;4.12</bold>
<sup>&#x02217;c</sup>
</td><td align="center" colspan="2" rowspan="1">
<bold>25.77&#x02009;&#x000b1;&#x02009;4.13</bold>
<sup>&#x02217;c</sup>
</td><td align="center" colspan="2" rowspan="1">
<bold>29.31&#x02009;&#x000b1;&#x02009;4.55</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ES</td><td align="center" colspan="2" rowspan="1">0.27</td><td align="center" colspan="2" rowspan="1">0.42</td><td align="center" colspan="2" rowspan="1">0.02</td></tr></tbody></table><table-wrap-foot><fn><p>Values are represented as mean&#x02009;&#x000b1;&#x02009;SD (<italic>n</italic> = 81 patients in the resveratrol 100&#x02009;mg group; <italic>n</italic> = 55 patients in the resveratrol 200&#x02009;mg group; and <italic>n</italic> = 92 patients in the control group); <sup>&#x02217;</sup><italic>p</italic> &#x0003c; 0.05 versus initial value; <sup>c</sup>&#x0003c;0.05 versus control group value.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Effect of resveratrol on the lipid profile.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Lipid profile</th><th align="center" colspan="2" rowspan="1">Resveratrol 100&#x02009;mg group</th><th align="center" colspan="2" rowspan="1">Resveratrol 200&#x02009;mg group</th><th align="center" colspan="2" rowspan="1">Control group</th></tr><tr><th align="center" rowspan="1" colspan="1">M&#x02009;&#x000b1;&#x02009;SD</th><th align="center" rowspan="1" colspan="1">ES</th><th align="center" rowspan="1" colspan="1">M&#x02009;&#x000b1;&#x02009;SD</th><th align="center" rowspan="1" colspan="1">ES</th><th align="center" rowspan="1" colspan="1">M&#x02009;&#x000b1;&#x02009;SD</th><th align="center" rowspan="1" colspan="1">ES</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">
<italic>Serum cholesterol (mg/dL)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial</td><td align="center" rowspan="1" colspan="1">257.56&#x000a0;&#x000b1;&#x000a0;23.89</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">256.61&#x000a0;&#x000b1;&#x000a0;22.23</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">255.14&#x000a0;&#x000b1;&#x000a0;22.08</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">At 6 months</td><td align="center" rowspan="1" colspan="1">236.75&#x000a0;&#x000b1;&#x000a0;22.82<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.87</td><td align="center" rowspan="1" colspan="1">236.16&#x000a0;&#x000b1;&#x000a0;22.61<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.92</td><td align="center" rowspan="1" colspan="1">247.25&#x000a0;&#x000b1;&#x000a0;21.67<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">At 12 months</td><td align="center" rowspan="1" colspan="1">221.52&#x000a0;&#x000b1;&#x000a0;21.75<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.67</td><td align="center" rowspan="1" colspan="1">220.44&#x000a0;&#x000b1;&#x000a0;21.56<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.70</td><td align="center" rowspan="1" colspan="1">231.41&#x000a0;&#x000b1;&#x000a0;20.78<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" colspan="7" rowspan="1">
<italic>HDL cholesterol (mg/dL)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial</td><td align="center" rowspan="1" colspan="1">39.27&#x000a0;&#x000b1;&#x000a0;5.27</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">39.36&#x000a0;&#x000b1;&#x000a0;5.16</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">38.76&#x000a0;&#x000b1;&#x000a0;5.29</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">At 6 months</td><td align="center" rowspan="1" colspan="1">43.78&#x000a0;&#x000b1;&#x000a0;5.28<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.86</td><td align="center" rowspan="1" colspan="1">43.92&#x000a0;&#x000b1;&#x000a0;5.18<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.88</td><td align="center" rowspan="1" colspan="1">40.17&#x000a0;&#x000b1;&#x000a0;5.21</td><td align="center" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">At 12 months</td><td align="center" rowspan="1" colspan="1">45.87&#x000a0;&#x000b1;&#x000a0;5.31<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.40</td><td align="center" rowspan="1" colspan="1">46.12&#x000a0;&#x000b1;&#x000a0;5.11<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">42.02&#x000a0;&#x000b1;&#x000a0;5.14<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" colspan="7" rowspan="1">
<italic>LDL cholesterol (mg/dL)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial</td><td align="center" rowspan="1" colspan="1">143.34&#x000a0;&#x000b1;&#x000a0;15.41</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">142.82&#x000a0;&#x000b1;&#x000a0;15.26</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">143.48&#x000a0;&#x000b1;&#x000a0;15.46</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">At 6 months</td><td align="center" rowspan="1" colspan="1">127.66&#x000a0;&#x000b1;&#x000a0;13.88<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">1.02</td><td align="center" rowspan="1" colspan="1">125.01&#x000a0;&#x000b1;&#x000a0;13.11<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">1.04</td><td align="center" rowspan="1" colspan="1">137.92&#x000a0;&#x000b1;&#x000a0;13.83<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">At 12 months</td><td align="center" rowspan="1" colspan="1">124.21&#x000a0;&#x000b1;&#x000a0;13.67<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.25</td><td align="center" rowspan="1" colspan="1">123.22&#x000a0;&#x000b1;&#x000a0;13.13<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.29</td><td align="center" rowspan="1" colspan="1">135.21&#x000a0;&#x000b1;&#x000a0;13.60<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" colspan="7" rowspan="1">
<italic>Triglycerides (mg/dL)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial</td><td align="center" rowspan="1" colspan="1">195.36&#x000a0;&#x000b1;&#x000a0;20.16</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">195.69&#x000a0;&#x000b1;&#x000a0;20.24</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">194.45&#x000a0;&#x000b1;&#x000a0;20.24</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">At 6 months</td><td align="center" rowspan="1" colspan="1">172.73&#x000a0;&#x000b1;&#x000a0;18.49<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">1.12</td><td align="center" rowspan="1" colspan="1">170.75&#x000a0;&#x000b1;&#x000a0;18.23<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">1.23</td><td align="center" rowspan="1" colspan="1">177.54&#x000a0;&#x000b1;&#x000a0;19.01<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" rowspan="1" colspan="1">At 12 months</td><td align="center" rowspan="1" colspan="1">158.78&#x000a0;&#x000b1;&#x000a0;16.85<sup>&#x02217;cr</sup></td><td align="center" rowspan="1" colspan="1">0.75</td><td align="center" rowspan="1" colspan="1">156.28&#x000a0;&#x000b1;&#x000a0;16.28<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.79</td><td align="center" rowspan="1" colspan="1">166.28&#x000a0;&#x000b1;&#x000a0;17.77<sup>&#x02217;</sup></td><td align="center" rowspan="1" colspan="1">0.59</td></tr></tbody></table><table-wrap-foot><fn><p>Values are represented as mean&#x02009;&#x000b1;&#x02009;SD (<italic>n</italic> = 81 patients in the resveratrol 100&#x02009;mg group; <italic>n</italic> = 55 patients in the resveratrol 200&#x02009;mg group; and <italic>n</italic> = 92 patients in the control group); <sup>&#x02217;</sup><italic>p</italic> &#x0003c; 0.05 versus initial value; <sup>c</sup>&#x0003c;0.05 versus control group value; <sup>r</sup>&#x0003c;0.05 versus resveratrol 200&#x02009;mg group value.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Effect of resveratrol on glucose.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Evaluation</th><th align="center" colspan="4" rowspan="1">Glucose (mg/dL)</th></tr><tr><th align="center" rowspan="1" colspan="1">Diabetics</th><th align="center" rowspan="1" colspan="1">ES</th><th align="center" rowspan="1" colspan="1">Nondiabetics</th><th align="center" rowspan="1" colspan="1">ES</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">
<italic>Resveratrol 100&#x02009;mg group</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial</td><td align="center" rowspan="1" colspan="1">142.18&#x000a0;&#x000b1;&#x000a0;15.22</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">96.67&#x000a0;&#x000b1;&#x000a0;11.26</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">At 6 months</td><td align="center" rowspan="1" colspan="1">136.29&#x000a0;&#x000b1;&#x000a0;14.48<sup>c</sup></td><td align="center" rowspan="1" colspan="1">0.39</td><td align="center" rowspan="1" colspan="1">91.23&#x000a0;&#x000b1;&#x000a0;10.75<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1">At 12 months</td><td align="center" rowspan="1" colspan="1">134.24&#x000a0;&#x000b1;&#x000a0;14.31</td><td align="center" rowspan="1" colspan="1">0.14</td><td align="center" rowspan="1" colspan="1">87.12&#x000a0;&#x000b1;&#x000a0;10.61<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" colspan="5" rowspan="1">
<italic>Resveratrol 200&#x02009;mg group</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial</td><td align="center" rowspan="1" colspan="1">142.46&#x000a0;&#x000b1;&#x000a0;15.24</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">96.98&#x000a0;&#x000b1;&#x000a0;11.23</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">At 6 months</td><td align="center" rowspan="1" colspan="1">136.21&#x000a0;&#x000b1;&#x000a0;14.56<sup>c</sup></td><td align="center" rowspan="1" colspan="1">0.41</td><td align="center" rowspan="1" colspan="1">91.21&#x000a0;&#x000b1;&#x000a0;10.67<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">At 12 months</td><td align="center" rowspan="1" colspan="1">133.89&#x000a0;&#x000b1;&#x000a0;15.68</td><td align="center" rowspan="1" colspan="1">0.16</td><td align="center" rowspan="1" colspan="1">86.11&#x000a0;&#x000b1;&#x000a0;10.78<sup>&#x02217;c</sup></td><td align="center" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" colspan="5" rowspan="1">
<italic>Control group</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial</td><td align="center" rowspan="1" colspan="1">142.47&#x000a0;&#x000b1;&#x000a0;15.83</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">95.71&#x000a0;&#x000b1;&#x000a0;11.63</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">At 6 months</td><td align="center" rowspan="1" colspan="1">141.81&#x000a0;&#x000b1;&#x000a0;15.31</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">94.55&#x000a0;&#x000b1;&#x000a0;11.22</td><td align="center" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" rowspan="1" colspan="1">At 12 months</td><td align="center" rowspan="1" colspan="1">140.58&#x000a0;&#x000b1;&#x000a0;15.62</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">93.33&#x000a0;&#x000b1;&#x000a0;11.28</td><td align="center" rowspan="1" colspan="1">0.11</td></tr></tbody></table><table-wrap-foot><fn><p>Values are represented as mean&#x02009;&#x000b1;&#x02009;SD (<italic>n</italic> = 13 diabetic and <italic>n</italic> = 68 nondiabetic patients in the resveratrol 100&#x02009;mg group; <italic>n</italic> = 11 diabetic and <italic>n</italic> = 44 nondiabetic patients in the resveratrol 200&#x02009;mg group; and <italic>n</italic> = 16 diabetic and <italic>n</italic> = 76 nondiabetic patients in the control group); <sup>&#x02217;</sup><italic>p</italic> &#x0003c; 0.05 versus initial value; <sup>c</sup>&#x0003c;0.05 versus control group value.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Effect of resveratrol on HbA1c.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1">Evaluation</th><th align="center" colspan="6" rowspan="1">HbA1c (%)</th></tr><tr><th align="center" colspan="2" rowspan="1">Resveratrol 100&#x02009;mg group</th><th align="center" colspan="2" rowspan="1">Resveratrol 200&#x02009;mg group</th><th align="center" colspan="2" rowspan="1">Control group</th></tr><tr><th align="center" rowspan="1" colspan="1">M&#x02009;&#x000b1;&#x02009;SD</th><th align="center" rowspan="1" colspan="1">ES</th><th align="center" rowspan="1" colspan="1">M&#x02009;&#x000b1;&#x02009;SD</th><th align="center" rowspan="1" colspan="1">ES</th><th align="center" rowspan="1" colspan="1">M&#x02009;&#x000b1;&#x02009;SD</th><th align="center" rowspan="1" colspan="1">ES</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Initial</td><td align="center" rowspan="1" colspan="1">7.13&#x000a0;&#x000b1;&#x000a0;1.51</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">7.15&#x000a0;&#x000b1;&#x000a0;1.50</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">7.10&#x000a0;&#x000b1;&#x000a0;1.47</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">At 6 months</td><td align="center" rowspan="1" colspan="1">6.72&#x000a0;&#x000b1;&#x000a0;1.40</td><td align="center" rowspan="1" colspan="1">0.27</td><td align="center" rowspan="1" colspan="1">6.66&#x000a0;&#x000b1;&#x000a0;1.41</td><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1">7.09&#x000a0;&#x000b1;&#x000a0;1.43</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">At 12 months</td><td align="center" rowspan="1" colspan="1">6.61&#x000a0;&#x000b1;&#x000a0;1.38</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">6.55&#x000a0;&#x000b1;&#x000a0;1.40</td><td align="center" rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">7.05&#x000a0;&#x000b1;&#x000a0;1.46</td><td align="center" rowspan="1" colspan="1">0.03</td></tr></tbody></table><table-wrap-foot><fn><p>Values are represented as mean&#x02009;&#x000b1;&#x02009;SD (<italic>n</italic> = 13 diabetic patients in the resveratrol 100&#x02009;mg group; <italic>n</italic> = 11 diabetic patients in the resveratrol 200&#x02009;mg group; and <italic>n</italic> = 16 diabetic patients in the control group).</p></fn></table-wrap-foot></table-wrap></floats-group></article>